Cargando…

Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid Biopsy

SIMPLE SUMMARY: Since the recent approval of osimertinib, a third generation tyrosine kinase inhibitor (TKI) targeting EGFR in non-small cell lung cancer (NSCLC), tracing the resistance mechanisms that yield to failure of osimertinib has become of interest. As the spectrum of osimertinib-resistance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jóri, Balázs, Schatz, Stefanie, Kaller, Len, Kah, Bettina, Roeper, Julia, Ramdani, Hayat O., Diehl, Linda, Hoffknecht, Petra, Grohé, Christian, Griesinger, Frank, Tiemann, Markus, Heukamp, Lukas C., Falk, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227553/ https://www.ncbi.nlm.nih.gov/pubmed/34201252 http://dx.doi.org/10.3390/cancers13122861

Ejemplares similares

Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer
por: Schatz, Stefanie, et al.
Publicado: (2020)

The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations
por: Jóri, Balázs, et al.
Publicado: (2023)

Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy
por: Jóri, Balázs, et al.
Publicado: (2022)

TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy—EGFR mutated non-small cell lung cancer IV patients treated with osimertinib
por: Roeper, Julia, et al.
Publicado: (2022)

TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC
por: Roeper, Julia, et al.
Publicado: (2020)

Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy
por: Falk, Markus, et al.
Publicado: (2023)

Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation
por: Willing, Eva-Maria, et al.
Publicado: (2023)

Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report
por: Falk, Markus, et al.
Publicado: (2023)

TAPO in first‐line osimertinib therapy and continuation of osimertinib
por: Mimura, Chihiro, et al.
Publicado: (2022)

Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy
por: Mambetsariev, Isa, et al.
Publicado: (2018)

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2020)

Modeling Photoassociative Spectra of Ultracold NaK + K
por: Shammout, Baraa, et al.
Publicado: (2023)

BCL9L expression in pancreatic neoplasia with a focus on SPN: a possible explanation for the enigma of the benign neoplasia
por: Hallas, Cora, et al.
Publicado: (2016)

Mechanisms of resistance to osimertinib
por: Lazzari, Chiara, et al.
Publicado: (2020)

Osimertinib-Induced Cardiomyopathy
por: Patel, Shruti R., et al.
Publicado: (2020)

Osimertinib‐related liver injury with successful osimertinib rechallenge: A case report
por: Cheng, Yuan‐Ling, et al.
Publicado: (2022)

Brain metastases in ALK-positive NSCLC – time to adjust current treatment algorithms
por: Griesinger, Frank, et al.
Publicado: (2018)

Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma
por: Satoh, Shingo, et al.
Publicado: (2017)

Successful Osimertinib Rechallenge with Steroid Therapy after Osimertinib-induced Interstitial Lung Disease
por: Kiriu, Tatsunori, et al.
Publicado: (2017)

Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
por: Saito, Zentaro, et al.
Publicado: (2023)

Optical Biopsy of the Upper GI Tract Using Fluorescence Lifetime and Spectra
por: Nie, Zhaojun, et al.
Publicado: (2020)

Osimertinib: Pneumonitis: case report
Publicado: (2021)

Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studies
por: Bickert, Christiane, et al.
Publicado: (2021)

Multiconfigurational Effects in Theoretical Resonance Raman Spectra
por: Ma, Yingjin, et al.
Publicado: (2017)

Combination of tissue and liquid biopsy molecular profiling to detect transformation to small cell lung carcinoma during osimertinib treatment
por: Vendrell, Julie A., et al.
Publicado: (2020)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab
por: Lopez, Michael, et al.
Publicado: (2023)

The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report
por: Hardenberg, M.C., et al.
Publicado: (2022)

Statistical analysis of ENDOR spectra
por: Pokern, Yvo, et al.
Publicado: (2021)

Finding chinks in the osimertinib resistance armor
por: Leal, Jose Luis, et al.
Publicado: (2020)

Sampling Method Affects HR-MAS NMR Spectra of Healthy Caprine Brain Biopsies
por: Häni, Annakatrin, et al.
Publicado: (2021)

Successful treatment with afatinib following the failure of osimertinib rechallenge with osimertinib-induced interstitial lung disease: A case report
por: Sato, Yozo, et al.
Publicado: (2021)

Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy
por: Kallergi, Galatea, et al.
Publicado: (2022)

Loss of p53-inducible long non-coding RNA LINC01021 increases chemosensitivity
por: Kaller, Markus, et al.
Publicado: (2017)

c-MYC-Induced AP4 Attenuates DREAM-Mediated Repression by p53
por: Kaller, Markus, et al.
Publicado: (2023)

CRISPR/Cas9-mediated inactivation of miR-34a and miR-34b/c in HCT116 colorectal cancer cells: comprehensive characterization after exposure to 5-FU reveals EMT and autophagy as key processes regulated by miR-34
por: Huang, Zekai, et al.
Publicado: (2023)

Osimertinib induced cardiomyopathy: A case report
por: Shinomiya, Shun, et al.
Publicado: (2020)

Efficacy of osimertinib against EGFRvIII+ glioblastoma
por: Chagoya, Gustavo, et al.
Publicado: (2020)

Osimertinib-associated ashy dermatosis–like hyperpigmentation
por: Lertpichitkul, Pattamon, et al.
Publicado: (2020)

1766. Osimertinib-Associated Progressive Multifocal Leucoencephalopathy
por: Gilotra, Tarvinder S, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dipf1kfsqf1srdnq86dnu73rcb